Published on: 24 April 2018
On 24 April the Medicines and Healthcare Products Regulatory Agency (MHRA) changed its regulatory position on medicines containing sodium valproate. MHRA advises that if a woman of childbearing age is to be prescribed sodium valproate, she must be enrolled in a pregnancy prevention programme (PPP). This FSRH statement outlines the implications for daily practice.
Your download should start automatically. If not download directly.